Cheng Hai

Cheng Hai

Auto-generated profile, based on publicly available information

Cheng Hai

Institute of Biopharmaceutical and Health Engineering, Tsinghua Shenzhen International Graduate School (SIGS), Tsinghua University, Shenzhen, China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2026 in Gut
Verified
Journal Article
Closed access
PDF file
CHCheng Hai
Cheng Hai
YHYibo Hou
Yibo Hou
SYSiyang Yu
Siyang Yu
XPXiaoyu Pan
Xiaoyu Pan
GNGeorge Michael Nicolas
George Michael Nicolas
SMShaohua Ma
Shaohua Ma
Background: Liver cancer exhibits profound spatial and cellular heterogeneity, contributing to tumour progression, invasion and therapeutic resistance. Emerging evidence suggests that rare low-abundance malignant cell populations residing within discrete tissue niches influence these processes. However, their reliable detection and identification remain challenging due to the limitations of conventional spatial and single-cell transcriptomic analyses, which often rely on single-sample convergence and a lack of cross-cohort reproducibility. Objective: To develop a robust framework for identifying rare malignant cell populations across heterogeneous spatial transcriptomic datasets and to characterise their functional role in liver cancer progression. Design: We developed the Niche Cluster Atlas with Cellular Co-localisation (NCACC), a dual-layer framework integrating spatial organisation with cellular composition to enable cross-sample niche discovery. NCACC was applied to a comprehensive liver cancer transcriptomic atlas to identify rare niche-associated malignant cell populations. Results: NCACC stratified liver cancer tumour architecture into reproducible multicellular niche modules and enabled a tumour-invasive front-enriched rare cancer-derived IgG (cIgG) + epithelial cell population. These cells enhanced proliferative and invasive characteristics and were associated with disease progression. Mechanistic analyses identified a STAT1-dependent cIgG-JAK-STAT signalling axis sustaining the invasive-front phenotype and promoting cIgG + epithelial cell aggressive behaviours. We then combined structure-guided virtual screening with patient-derived organoid validation to identify nordihydroguaiaretic acid and gallic aldehyde as candidate modulators. Conclusion: Our study establishes NCACC as a generalisable framework for high-confidence rare malignant cell identification across heterogeneous spatial transcriptomic cohorts, highlighting the cIgG-JAK-STAT as a therapeutically actionable driver of liver cancer invasion.